A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Inclusion Criteria:

• Primary diagnosis of panic disorder based on Diagnostic and Statistical Manual ofMental Disorders, Fifth Edition Text Revision (DSM-5-TR), as confirmed by theStandard Mini International Neuropsychiatric Interview (MINI)

• Participant has had a minimum of 8 panic attacks, with no week free of panicattacks, in the month prior to the Screening Visit. In the 2 weeks prior to theBaseline Visit, the participant must have had at least 4 panic attacks and no weekfree of panic attacks

• Participants with a PDSS total score ≥12 at the Screening and Baseline Visits

• Body mass index of 17.5 to 40.0 kilograms per meter square (kg/m2) and a total bodyweight >48 kg at Screening

Exclusion Criteria:

• Participants who have a current significant psychiatric comorbidity

• Any newly initiated evidence-based psychotherapy, including cognitive behavioraltherapy (CBT)

• Any exposure-based therapy is prohibited throughout the duration of the trial

• Participants with a current history of significant cardiovascular, pulmonary,gastrointestinal, renal, hepatic, metabolic, hematological, immunological, orneurological disease

• Participants who answer "Yes" on the following C-SSRS Suicidal Ideation Items (within the last 6 months)

• Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act,Without Specific Plan) OR

• Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan andIntent) OR Participants who answer "Yes" on any of the 5 C-SSRS SuicidalBehavior Items (within the last 2 years)

• Any of the Suicidal Behavior items (actual attempt, interrupted attempt,aborted attempt, preparatory acts, or behavior) OR

• Participants who, in the opinion of the investigator, present a serious risk ofsuicide

NOTE: Other protocol-defined inclusion/exclusion criteria may apply